Search | Clinical Trials Finder

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Neurogenic Detrusor Overactivity
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Tarrytown, New York • Cincinnati, Ohio

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 58
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more

Conditions: Urinary Bladder, Overactive
Interventions: solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 198
States / cities: Bay Minette, Alabama • Birmingham, Alabama • Decatur, Alabama + 171 more

Conditions: Hot Flashes, Breast Cancer
Interventions: solifenacin, Clonidine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Urinary Incontinence, Urgency Urinary
Interventions: Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease
Interventions: CPC-201, Positron emission tomography (PET); Drug · Other
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, tamsulosin, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more

Conditions: Urge Urinary Incontinence
Interventions: Solifenacin; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Over-Active Bladder
Interventions: Solifenacin succinate, Placebo; Drug
Lead sponsor: Advanced Research Network; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overactive Bladder
Interventions: Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification; Drug · Behavioral
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Urethral Sphincter Activity
Interventions: Pseudoephedrine, Tamsulosin, Imipramine, Cyclobenzaprine, Lactose capsule, Solifenacin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 51 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions: solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more

Conditions: Urinary Incontinence, Parkinson's Disease
Interventions: Solifenacin Succinate (VESIcare), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 30 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: fesoterodine fumarate, placebo, solifenacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride; Drug
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Conditions: Urinary Incontinence
Interventions: Vesicare; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Orange, California

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin Succinate Suspension, Placebo, Urotherapy; Drug · Behavioral
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Albany, New York

Conditions: Pelvic Organ Prolapse
Interventions: Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex; Drug · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Urinary Bladder, Overactive
Interventions: solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 104
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more

Conditions: Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions: Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT); Drug · Diagnostic Test
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Temple, Texas

Conditions: Urinary Bladder, Overactive
Interventions: VESIcare®, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 65
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more

Conditions: Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions: solifenacin succinate, placebo; Drug
Lead sponsor: Stamford Hospital; Other
Eligibility: 20 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Stamford, Connecticut

Search by objective public record fields.

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

CPC-201 Alzheimer's Disease Type Dementia: PET Study

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

Incontinence & Intimate Partners: Assessing the Contribution of Treatment

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Anticholinergic vs. Botox Comparison Study

Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder